Key information

🔎 Fund Overview

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapies. The Company concentrates on small-molecule therapeutics with mechanisms of action for the treatment of severe, life-threatening diseases. Its lead programs are omaveloxolone in a rare neurological disease called Friedreich's ataxia (FA) and bardoxolone in rare forms of chronic kidney disease (CKD). Both of its lead product candidates activate the transcription factor Nrf2 to normalize mitochondrial function, restore redox balance, and resolve inflammation. It possesses worldwide rights to develop, manufacture, and commercialize omaveloxolone, bardoxolone, and other Nrf2 activators, excluding certain Asian markets for bardoxolone in certain indications. In addition, the Company is developing cemdomespib, the lead product candidate from its Hsp90 modulator program, in neurological indications. The Company has three pipeline programs for CKD.